1
|
Brusosa M, Ruiz S, Monge I, Solano MT, Rosiñol L, Esteve J, Carreras E, Marcos MÁ, Riu G, Carcelero E, Martinez C, Fernández-Avilés F, Rovira M, Suárez-Lledó M, Salas MQ. Impact of letermovir prophylaxis in CMV reactivation and disease after allogenic hematopoietic cell transplantation: a real-world, observational study. Ann Hematol 2024; 103:609-621. [PMID: 37957371 DOI: 10.1007/s00277-023-05542-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Accepted: 11/05/2023] [Indexed: 11/15/2023]
Abstract
Letermovir for CMV prevention in CMV-seropositive adults undergoing allo-HCT was implemented at our program in 2021. This study investigates the results from the use of letermovir. The study includes all the 140 CMV-seropositive patients who underwent an allo-HCT during the years 2020, 2021, and 2022 at our institution. Thirty-eight (27.4%) of these patients received letermovir, administered from day + 7 to day + 100 and restarted if patients were on treatment with steroids. The day + 180 and 1-year cumulative incidences of CMV reactivation were 5.3% and 12.1% for patients who received letermovir and 52.9% and 53.9% for those who did not (P < 0.001) (HR 0.19, P < 0.001). Four (10.5%) of these thirty-eight patients had a CMV reactivation, but only 2 (5.3%) cases occurred during the administration of letermovir. During the first year after allo-HCT, 13 (9.2%) patients had CMV disease; the day + 180 and 1-year cumulative incidences were 2.6% and 6.0% for patients who received letermovir and 9.9% and 12.3% for those who did not (P = 0.254) (HR 1.01, P = 0.458). Two (4.2%) of the patients included in the letermovir group had CMV disease, but both of them after letermovir discontinuation. Letermovir induced a protective effect on CMV reactivation risk, but its use was not associated with a significant reduction of CMV disease. The fact that the CMV disease in patients who received letermovir occurred after the discontinuation of the drug, questions whether CMV prophylaxis should be used in patients with high risk for CMV reactivation or disease.
Collapse
Affiliation(s)
| | - Sonia Ruiz
- Pharmacy Clinic Department, Hospital Clínic de Barcelona, Barcelona, Spain
| | - Inés Monge
- Pharmacy Clinic Department, Hospital Clínic de Barcelona, Barcelona, Spain
| | - María Teresa Solano
- Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hematopoietic Transplantation Unit, Hospital Clínic de Barcelona, C/ Villarroel 190, 08036, Barcelona, CP, Spain
| | - Laura Rosiñol
- University of Barcelona, Barcelona, Spain
- Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hematopoietic Transplantation Unit, Hospital Clínic de Barcelona, C/ Villarroel 190, 08036, Barcelona, CP, Spain
- Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| | - Jordi Esteve
- University of Barcelona, Barcelona, Spain
- Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hematopoietic Transplantation Unit, Hospital Clínic de Barcelona, C/ Villarroel 190, 08036, Barcelona, CP, Spain
- Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| | - Enric Carreras
- Fundació I Institut de Recerca Josep Carreras Contra La Leucèmia, Barcelona, Spain
| | - M Ángeles Marcos
- Department of Microbiology, Hospital Clínic-ISGlobal, University of Barcelona, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
| | - Gisela Riu
- Pharmacy Clinic Department, Hospital Clínic de Barcelona, Barcelona, Spain
| | - Esther Carcelero
- Pharmacy Clinic Department, Hospital Clínic de Barcelona, Barcelona, Spain
| | - Carmen Martinez
- University of Barcelona, Barcelona, Spain
- Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hematopoietic Transplantation Unit, Hospital Clínic de Barcelona, C/ Villarroel 190, 08036, Barcelona, CP, Spain
- Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| | - Francesc Fernández-Avilés
- University of Barcelona, Barcelona, Spain
- Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hematopoietic Transplantation Unit, Hospital Clínic de Barcelona, C/ Villarroel 190, 08036, Barcelona, CP, Spain
- Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| | - Montserrat Rovira
- University of Barcelona, Barcelona, Spain
- Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hematopoietic Transplantation Unit, Hospital Clínic de Barcelona, C/ Villarroel 190, 08036, Barcelona, CP, Spain
- Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| | - María Suárez-Lledó
- University of Barcelona, Barcelona, Spain
- Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hematopoietic Transplantation Unit, Hospital Clínic de Barcelona, C/ Villarroel 190, 08036, Barcelona, CP, Spain
- Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| | - María Queralt Salas
- University of Barcelona, Barcelona, Spain.
- Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hematopoietic Transplantation Unit, Hospital Clínic de Barcelona, C/ Villarroel 190, 08036, Barcelona, CP, Spain.
- Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.
| |
Collapse
|
2
|
Gómez-Hernando M, Quintana LF, Suárez-Lledo M, Martínez-Cibrian N, Rivero A, Ruiz-Boy S, Carcelero E, Mate P, Riu G, Monge I, Serrahima A, Solano MT, Rosiñol L, Esteve J, Urbano-Ispizua A, Carreras E, Fernández-Avilés F, Martínez C, Rovira M, Salas MQ. Hyponatremia induced by post-transplant cyclophosphamide in allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2023; 58:212-214. [PMID: 36335256 DOI: 10.1038/s41409-022-01864-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2022] [Revised: 10/21/2022] [Accepted: 10/26/2022] [Indexed: 11/08/2022]
Affiliation(s)
- Marta Gómez-Hernando
- Hematopoietic Transplantation Unit, Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hospital Clínic de Barcelona, Barcelona, Spain
| | - Luis F Quintana
- Clinical Nephrology Section, Nephrology and Renal Transplantation Department, Hospital Clínic de Barcelona, ICNU, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Department of Medicine, University of Barcelona, Barcelona, Spain
| | - María Suárez-Lledo
- Hematopoietic Transplantation Unit, Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hospital Clínic de Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Nuria Martínez-Cibrian
- Hematopoietic Transplantation Unit, Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hospital Clínic de Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Andrea Rivero
- Hematopoietic Transplantation Unit, Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hospital Clínic de Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Sonia Ruiz-Boy
- Pharmacy Unit, Hospital Clínic de Barcelona, Barcelona, Spain
| | - Ester Carcelero
- Pharmacy Unit, Hospital Clínic de Barcelona, Barcelona, Spain
| | - Paula Mate
- Pharmacy Unit, Hospital Clínic de Barcelona, Barcelona, Spain
| | - Gisela Riu
- Pharmacy Unit, Hospital Clínic de Barcelona, Barcelona, Spain
| | - Inés Monge
- Pharmacy Unit, Hospital Clínic de Barcelona, Barcelona, Spain
| | - Anna Serrahima
- Hematopoietic Transplantation Unit, Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hospital Clínic de Barcelona, Barcelona, Spain
| | - Maria Teresa Solano
- Hematopoietic Transplantation Unit, Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hospital Clínic de Barcelona, Barcelona, Spain
| | - Laura Rosiñol
- Hematopoietic Transplantation Unit, Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hospital Clínic de Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Department of Medicine, University of Barcelona, Barcelona, Spain
| | - Jordi Esteve
- Hematopoietic Transplantation Unit, Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hospital Clínic de Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Department of Medicine, University of Barcelona, Barcelona, Spain
| | - Alvaro Urbano-Ispizua
- Hematopoietic Transplantation Unit, Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hospital Clínic de Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Department of Medicine, University of Barcelona, Barcelona, Spain
| | - Enric Carreras
- Fundació i Institut de Recerca Josep Carreras contra la leucèmia (Campus Clínic), Barcelona, Spain
| | - Francesc Fernández-Avilés
- Hematopoietic Transplantation Unit, Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hospital Clínic de Barcelona, Barcelona, Spain.,Department of Medicine, University of Barcelona, Barcelona, Spain
| | - Carmen Martínez
- Hematopoietic Transplantation Unit, Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hospital Clínic de Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Department of Medicine, University of Barcelona, Barcelona, Spain
| | - Montserrat Rovira
- Hematopoietic Transplantation Unit, Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hospital Clínic de Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Department of Medicine, University of Barcelona, Barcelona, Spain
| | - Maria Queralt Salas
- Hematopoietic Transplantation Unit, Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hospital Clínic de Barcelona, Barcelona, Spain. .,Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
| |
Collapse
|
3
|
Marco DN, Salas MQ, Gutiérrez-García G, Monge I, Riu G, Carcelero E, Roma JR, Llobet N, Arcarons J, Suárez-Lledó M, Martínez N, Pedraza A, Domenech A, Rosiñol L, Fernández-Avilés F, Urbano-Ispízua Á, Rovira M, Brunet M, Martínez C. Impact of Early Intrapatient Variability of Tacrolimus Concentrations on the Risk of Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide. Pharmaceuticals (Basel) 2022; 15:ph15121529. [PMID: 36558980 PMCID: PMC9784628 DOI: 10.3390/ph15121529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2022] [Revised: 12/02/2022] [Accepted: 12/05/2022] [Indexed: 12/13/2022] Open
Abstract
Tacrolimus (Tac) is a pivotal immunosuppressant agent used to prevent graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (alloHSCT). Tac is characterized by a narrow therapeutic window and a high inter-patient and intra-patient pharmacokinetic variability (IPV). Although high IPV of Tac concentrations has been associated with adverse post-transplant outcomes following solid organ transplantation, the effects of Tac IPV on alloHSCT recipients have not been determined. Tac IPV was therefore retrospectively evaluated in 128 alloHSCT recipients receiving high-dose post-transplant cyclophosphamide (PTCy) and the effects of Tac IPV on the occurrence of acute GVHD (aGVHD) were analyzed. Tac IPV was calculated from pre-dose concentrations (C0) measured during the first month after Tac initiation. The cumulative rates of grades II-IV and grades III-IV aGVHD at day +100 were 22.7% and 7%, respectively. Higher Tac IPV was associated with a greater risk of developing GVHD, with patients having IPV > 50th percentile having significantly higher rates of grades II-IV (34.9% vs. 10.8%; hazard ratio [HR] 3.858, p < 0.001) and grades III-IV (12.7% vs. 1.5%; HR 9.69, p = 0.033) aGVHD than patients having IPV ≤ 50th percentile. Similarly, patients with IPV > 75th percentile had higher rates of grades II-IV (41.9% vs. 16.5%; HR 3.30, p < 0.001) and grades III-IV (16.1% vs. 4.1%; HR 4.99, p = 0.012) aGVHD than patients with IPV ≤ 75th percentile. Multivariate analyses showed that high Tac IPV (>50th percentile) was an independent risk factor for grades II-IV (HR 2.99, p = 0.018) and grades III-IV (HR 9.12, p = 0.047) aGVHD. Determination of Tac IPV soon after alloHSCT could be useful in identifying patients at greater risk of aGVHD.
Collapse
Affiliation(s)
- Daniel N. Marco
- Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, 08036 Barcelona, Spain
| | - María Queralt Salas
- Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, 08036 Barcelona, Spain
| | - Gonzalo Gutiérrez-García
- Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, 08036 Barcelona, Spain
| | - Inés Monge
- Department of Pharmacy, Pharmacy Service, Hospital Clínic, IDIBAPS, 08036 Barcelona, Spain
| | - Gisela Riu
- Department of Pharmacy, Pharmacy Service, Hospital Clínic, IDIBAPS, 08036 Barcelona, Spain
| | - Esther Carcelero
- Department of Pharmacy, Pharmacy Service, Hospital Clínic, IDIBAPS, 08036 Barcelona, Spain
| | - Joan Ramón Roma
- Department of Pharmacy, Pharmacy Service, Hospital Clínic, IDIBAPS, 08036 Barcelona, Spain
| | - Noemí Llobet
- Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, 08036 Barcelona, Spain
| | - Jordi Arcarons
- Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, 08036 Barcelona, Spain
| | - María Suárez-Lledó
- Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, 08036 Barcelona, Spain
| | - Nuria Martínez
- Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, 08036 Barcelona, Spain
| | - Alexandra Pedraza
- Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, 08036 Barcelona, Spain
| | - Ariadna Domenech
- Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, 08036 Barcelona, Spain
| | - Laura Rosiñol
- Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, 08036 Barcelona, Spain
| | - Francesc Fernández-Avilés
- Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, 08036 Barcelona, Spain
| | - Álvaro Urbano-Ispízua
- Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, 08036 Barcelona, Spain
| | - Montserrat Rovira
- Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, 08036 Barcelona, Spain
| | - Mercè Brunet
- Pharmacology and Toxicology Laboratory, Biochemistry and Molecular Genetics Department, Biomedical Diagnostic Center, Hospital Clínic, IDIBAPS, 08036 Barcelona, Spain
| | - Carmen Martínez
- Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, 08036 Barcelona, Spain
- Correspondence: ; Tel.: +34-93-227-54-28; Fax: +34-93-227-54-84
| |
Collapse
|
4
|
Lahoz S, Rodriguez Hernandez A, Fernandez-Mañas L, Gorria T, Zambrano R, Esposito F, Sauri Nadal T, Pesantez Coronel D, Riu G, Cuatrecasas M, Jares P, Pedrosa L, Pineda E, Postigo A, Castells A, Prat A, Maurel J, Camps J. 352P Mutations of SMAD4 and FBXW7 predict poor outcome in TP53-driven metastatic colorectal cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
5
|
Gorría Puga T, Teixidó C, Auclin E, Gataa I, Nalda I, Reyes R, Rodriguez A, Riudavets Melia M, Aldea M, Seguí E, Riu G, Arcocha A, Prat A, Viñolas N, Planchard D, Martinez D, Reguart N, Adam J, Besse B, Mezquita L. 184P Association of tumor-associated neutrophils (TAN) with immunotherapy outcomes in patients in advanced non-small cell lung cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
6
|
Chaguaceda C, Aguilera-Jiménez V, Gutierrez G, Roura J, Riu G. Oral levetiracetam for prevention of busulfan-induced seizures in adult hematopoietic cell transplant. Int J Clin Pharm 2020; 42:351-354. [PMID: 32026356 DOI: 10.1007/s11096-020-00977-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2019] [Accepted: 01/18/2020] [Indexed: 11/27/2022]
Abstract
Background Antiseizure prophylaxis is recommended when high-dose of busulfan is given as part of the conditioning regimens in the allogenic hematopoietic stem cell transplant. Phenytoin has been widely used but its pharmacokinetics and pharmacodynamics profile makes its use complicated. Levetiracetam is a safe, effective and well tolerated antiseizure drug with good results in epileptic patients. Objective To describe our experience using oral (p.o) levetiracetam 1000 mg every 12 h (q12h) as an antiseizure prophylaxis, evaluating its preventive effects and adverse event rates after a high-dose of intravenous (i.v.) busulfan, as part of the conditioning regimen Methods Retrospective study of patients who underwent an allogenic hematopoietic stem cell transplant with a conditioning regimen based on high-dose of busulfan between January and November 2017. Results The study population comprised 36 patients, of whom 18 (50%) had acute myeloid leukemia as diagnosis. No seizures occurred in any patient. Levetiracetam was well tolerated and no serious adverse events were reported. Conclusions Our results suggest that giving levetiracetam at 1000 mg q12h p.o starting 12 h before the administration of i.v. busulfan until 48 h after the last dose, can be used as an alternative in the prevention of busulfan-induced seizures in adults.
Collapse
Affiliation(s)
- Cristian Chaguaceda
- Pharmacy Department, Hospital Clinic Barcelona, University of Barcelona, Barcelona, Spain.
- Pharmacy Department, Consorci Sanitari de Terrassa, Catalonia, Spain.
| | | | - Gonzalo Gutierrez
- Department of Hematology, Hospital Clinic Barcelona, University of Barcelona, Barcelona, Spain
| | - Judit Roura
- Pharmacy Department, Hospital Clinic Barcelona, University of Barcelona, Barcelona, Spain
| | - Gisela Riu
- Pharmacy Department, Hospital Clinic Barcelona, University of Barcelona, Barcelona, Spain
| |
Collapse
|
7
|
Pascual T, Gonzalez-Farre B, Teixidó C, Oleaga L, Oses G, Ganau S, Chic N, Riu G, Adamo B, Galván P, Vidal M, Soy D, Urbano Á, Muñoz M, Prat A. Significant Clinical Activity of Olaparib in a Somatic BRCA1-Mutated Triple-Negative Breast Cancer With Brain Metastasis. JCO Precis Oncol 2019; 3:1-6. [DOI: 10.1200/po.19.00012] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Affiliation(s)
| | | | | | | | | | - Sergi Ganau
- Hospital Clinic of Barcelona, Barcelona, Spain
| | - Nuria Chic
- Hospital Clinic of Barcelona, Barcelona, Spain
| | - Gisela Riu
- Hospital Clinic of Barcelona, Barcelona, Spain
| | | | | | - Maria Vidal
- Hospital Clinic of Barcelona, Barcelona, Spain
| | - Dolors Soy
- Hospital Clinic of Barcelona, Barcelona, Spain
| | | | | | - Aleix Prat
- Hospital Clinic of Barcelona, Barcelona, Spain
| |
Collapse
|
8
|
Porcu S, Battacone G, Diaferia C, Riu G, Piredda G. Un processo innovativo per la produzione di un piatto tradizionale della Sardegna: il maialetto (Porcheddu) arrosto. ARCH ZOOTEC 2018. [DOI: 10.21071/az.v67isupplement.3599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Il suinetto arrosto (Porcheddu) è uno dei piatti tradizionali della Sardegna più apprezzati, questo è
Collapse
|
9
|
Comunian R, Piras F, Di Salvo R, Paba A, Riu G, Addis M, De Santis E, Porcu S. Durata di conservazione della carne di suinetto sardo tradizionale e trattata termicamente e confezionata sottovuoto. ARCH ZOOTEC 2018. [DOI: 10.21071/az.v67isupplement.3597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Il suinetto da latte arrosto è un piatto tradizionale della Sardegna ampiamente consumato in tutta l’isola e molto apprezzato dai turisti. Purtroppo, a causa della recrudescenza della peste suina africana (PSA) nell’isola, è stata vietata l’esportazione di carni suine fresche e/o prodotti derivati. Alcune precauzioni necessarie per ottenere il permesso di esportare i prodotti a base di carne di maiale sono contenute nel provvedimento attuativo del Programma straordinario di eradicazione della PSA 2015-2017 emanato dal Governo Regionale. Una di queste consiste nel trattamento termico di precottura della carne fino al raggiungimento di una temperatura di 80 °C in tutta la massa. L’esportazione della carne di maiale rappresenta un’importante opportunità economica per gli operatori sardi del settore, fortemente interessati alla dimostrazione dell’efficacia e applicabilità del trattamento termico per garantire la sicurezza e la qualità dei loro prodotti. Lo scopo di questo studio era quello di valutare, mensilmente, da 0 a 150 giorni, la shelf-life dei campioni di carne trattati termicamente e conservati sottovuoto a 4 °C. Pertanto, cinque mezzene di suinetto, per punto di campionamento, sono state analizzate da un punto di vista microbiologico (conta di batteri patogeni e dannosi) e chimico (perossidazione lipidica), prima del completamento della cottura. Dopo 40 min in forno a 210 °C, è stato eseguito test di accettabilità sensoriale, per valutare il gradimento dei consumatori. I risultati ottenuti consentono di concludere che, la contaminazione microbica post-processo non ha determinato un decadimento della qualità e dell’accettabilità sensoriale del prodotto, fino a 150 giorni di shelf-life. I risultati evidenziano la necessità di prendere in considerazione l’applicazione di un trattamento post-letale per ridurre la contaminazione microbica.
Collapse
|
10
|
Riu G, Gaba L, Victoria I, Molas G, do Pazo F, Gómez B, Creus N, Vidal L. Implementation of a pharmaceutical care programme for patients receiving new molecular-targeted agents in a clinical trial unit. Eur J Cancer Care (Engl) 2016; 27. [PMID: 26786594 DOI: 10.1111/ecc.12447] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/22/2015] [Indexed: 01/20/2023]
Abstract
A pharmaceutical care programme was implemented at our hospital in early 2013. The main objectives were to analyse and describe the pharmaceutical interventions made, to calculate adherence, interventions and to evaluate patient satisfaction with the care programme. We performed a single-centre descriptive and prospective intervention in cancer patients who received oral chemotherapy as part of a clinical trial in 2013. Eighty-three patients were included. Median age was 58 years (range, 31-80) and 42 patients (50.6%) were men. We recorded 23 interventions, 13 of which were associated with drug interactions. The mean percentage of adherence was 98.9%. The interview with the pharmacist was considered to be very important by 84.6% of the respondents. A total of 92.3% said that they would like to speak to the pharmacist at subsequent visits. The doubts detected during the visits enable us to conclude that the information patients receive with respect to their study medication is usually incomplete. An integrated pharmaceutical care programme for cancer patients participating in clinical trials with oral cytostatic drugs was successful in terms of adherence and patient satisfaction and makes it possible to guarantee the safety and effectiveness of treatment on an individual basis.
Collapse
Affiliation(s)
- G Riu
- Department of Pharmacy, Hospital Clinic Barcelona, Barcelona, Spain
| | - L Gaba
- Department of Medical Oncology, Hospital Clinic Barcelona, Barcelona, Spain
| | - I Victoria
- Department of Medical Oncology, Hospital Clinic Barcelona, Barcelona, Spain
| | - G Molas
- Department of Pharmacy, Hospital Clinic Barcelona, Barcelona, Spain
| | - F do Pazo
- Department of Pharmacy, Hospital Clinic Barcelona, Barcelona, Spain
| | - B Gómez
- Department of Pharmacy, Hospital Clinic Barcelona, Barcelona, Spain
| | - N Creus
- Department of Pharmacy, Hospital Clinic Barcelona, Barcelona, Spain
| | - L Vidal
- Department of Medical Oncology, Hospital Clinic Barcelona, Barcelona, Spain
| |
Collapse
|
11
|
Esteban D, Tovar N, Jiménez R, Santacruz R, Baumann T, Pastor MC, de la Riva A, Carrera E, Chaves S, Royo C, Navarro A, Rodríguez S, Ayuso C, Riu G, Creus N, Gómez B, Giné E, López-Guillermo A, Delgado J. Patients with relapsed/refractory chronic lymphocytic leukaemia may benefit from inclusion in clinical trials irrespective of the therapy received: a case-control retrospective analsysis. Blood Cancer J 2015; 5:e356. [PMID: 26430727 PMCID: PMC4635190 DOI: 10.1038/bcj.2015.78] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- D Esteban
- Department of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - N Tovar
- Department of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - R Jiménez
- Department of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - R Santacruz
- Department of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - T Baumann
- Department of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - M C Pastor
- Department of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - A de la Riva
- Department of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - E Carrera
- Department of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - S Chaves
- Department of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - C Royo
- Haematopathology Unit, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - A Navarro
- Haematopathology Unit, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - S Rodríguez
- Department of Radiology, Hospital Clínic, Barcelona, Spain
| | - C Ayuso
- Department of Radiology, Hospital Clínic, Barcelona, Spain
| | - G Riu
- Department of Pharmacy, Hospital Clínic, Barcelona, Spain
| | - N Creus
- Department of Pharmacy, Hospital Clínic, Barcelona, Spain
| | - B Gómez
- Department of Pharmacy, Hospital Clínic, Barcelona, Spain
| | - E Giné
- Department of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - A López-Guillermo
- Department of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - J Delgado
- Department of Haematology, Hospital Clínic, IDIBAPS, Barcelona, Spain
| |
Collapse
|
12
|
Vidal Boixader L, Gaba L, Victoria I, Brunet M, Paredes P, Buxo E, Vilella T, Riu G, Cortal M, Gomez-Ferreria M, Alfon J, Domenech C, Gascon P. Dose-escalation of the first-in human phase I/Ib study of ABTL0812, a novel antitumor drug inhibiting the Akt/mTOR pathway in patients with advanced solid tumors. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.2585] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Lydia Gaba
- Hospital Clinic de Barcelona, Barcelona, Spain
| | - Iván Victoria
- Department of Medical Oncology, Hospital Clínic de Barcelona, Barcelona, Spain
| | | | - Pilar Paredes
- Nuclear Medicine Department, Hospital Clinic, Barcelona, Spain
| | | | | | | | - Marc Cortal
- Ability Pharmaceuticals SL, Bellaterra, Spain
| | | | - Jose Alfon
- Ability Pharmaceuticals SL, Bellaterra, Spain
| | | | | |
Collapse
|
13
|
Riu G, Victoria I, Garcia LG, Molas G, Pazo FD, Creus N, Gomez B, Vidal L. Implementation of a Pharmaceutical Care Programme for Patients Treated with Investigational Oral Drugs in a Clinical Trials Unit. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu331.48] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Riu G, Gaba L, Victoria I, Molas G, Do Pazo F, Creus N, Vidal L. PS-081 Implementation of a pharmaceutical care programme for patients treated with investigational oral drugs in a clinical trials unit. Eur J Hosp Pharm 2014. [DOI: 10.1136/ejhpharm-2013-000436.431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
15
|
Manca C, Addis M, Riu G, Fiori M, Scintu M. Physicochemical Properties of Different Muscles from Sarda Suckling Lambs Covered by the Protected Geographical Indication “Agnello di Sardegna”. J FOOD QUALITY 2013. [DOI: 10.1111/jfq.12040] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Affiliation(s)
- C. Manca
- Dipartimento per la Ricerca nelle Produzioni Animali; AGRIS Sardegna; 07040 Olmedo Italy
| | - M. Addis
- Dipartimento per la Ricerca nelle Produzioni Animali; AGRIS Sardegna; 07040 Olmedo Italy
| | - G. Riu
- Dipartimento per la Ricerca nelle Produzioni Animali; AGRIS Sardegna; 07040 Olmedo Italy
| | - M. Fiori
- Dipartimento per la Ricerca nelle Produzioni Animali; AGRIS Sardegna; 07040 Olmedo Italy
| | - M.F. Scintu
- Dipartimento per la Ricerca nelle Produzioni Animali; AGRIS Sardegna; 07040 Olmedo Italy
| |
Collapse
|
16
|
Mazzette R, Colleo M, Riu G, Piras G, Piras F, Addis M, Pes M, Pirisi A, Meloni D, Mureddu A, Spada S, Fiori M, Coinu M, Lentini A. PRODUCTION UNDER CONTROLLED CONDITIONS OF “CASU MARZU” CHEESE: EFFECT OF THE Piophila Casei COLONIZATION ON MICROBIAL AND CHEMICAL COMPOSITION OF THE CHEESES. Ital J Food Saf 2010. [DOI: 10.4081/ijfs.2010.7.45] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
17
|
Riu PL, Riu G, Testa C, Mulas M, Caria MA, Mameli S, Mameli O. Disposition of propofol between red blood cells, plasma, brain and cerebrospinal fluid in rabbits. Eur J Anaesthesiol 2000; 17:18-22. [PMID: 10758439 DOI: 10.1046/j.1365-2346.2000.00573.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The disposition of propofol in the blood and brain of New Zealand rabbits was studied in three groups of six rabbits. One group received a single anaesthetic dose; a second group received a 1-h infusion; and a third group was studied after the rabbits were judged to have recovered from a 1-h infusion. There was a high concentration of propofol in the red blood cell fraction and in the brain, however, the red blood cell concentration largely exceeded the one found in the brain in all groups of animals. This is consistent with the high fat solubility of diisopropylphenol. The possible effects of propofol sequestered in red blood cells is discussed.
Collapse
Affiliation(s)
- P L Riu
- Department of Traumatology, Orthopedy and Occupational Medicine, Turin University, Sassari, Italy
| | | | | | | | | | | | | |
Collapse
|